4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of$ 0.72. This compares to loss of $0.77 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 12.50%. A quarter ago, it was expected that this company would post a loss of$ 0.73 per share when it actually produced a loss of $0.66, delivering a surprise of 9.59%. Over the last four quarters, the com ...